The Australian Government has appointed Emeritus Professor Ian Chubb AC, FAA FTSE to lead key reforms as Chair of the Inter-Governmental Policy Reform Group (IGPRG) for health and medical research, including clinical trials.
Minister for Health and Aged Care, The Hon Mark Butler MP commenting on the selection and appointment said, “Professor Chubb has dedicated his career to improving health and medical research and education in this county and I am pleased he has agreed to share his knowledge and experience through the IGPRG.”
All Australian health ministers agreed to establish the enduring IGPRG, which will provide policy and operational oversight of the National One Stop Shop for health and medical research.
Professor Chubb spoke with Australian Health Journal about his career as Chief Scientist for Australia, personal patient experience with a clinical trial and also the consultation done to date on clinical trial and medical research reform.
The National One Stop Shop Program will transform health and medical research in Australia, by making it easier for patients, researchers and sponsors to find, conduct and participate in clinical trials and research.
It will deliver innovative treatments and improved health outcomes, increase productivity and sustainability in the health system, create jobs and help grow Australia’s innovation economy.
Minister Butler attending the MedTech23 conference hosted by The Medical Technology Association of Australia in Sydney yesterday said,
“A One Stop Shop for cutting-edge clinical trials will ensure that Australian patients and researchers are among the first to benefit from new life-changing and life-saving medicines.
I have asked my department to work with states and territories on the next phase of analysis and platform specification as a priority.“
The IGPRG will also have a key role in implementing and regulating the National Clinical Trials Governance Framework which will ensure a nationally consistent approach to clinical trials.
He has been integral to the development of the One Stop Shop to date, having already led the national consultations on the design of the program.
Representing the medical technology industry MTAA CEO Ian Burgess supported the establishment of the IGPRG and the appointment of Chair Professor Chubb. He added, “There is an opportunity to maximise the potential of clinical trials in Australia by increasing the MedTech clinical trials beyond the 394 currently underway, through the One Stop Shop Program and work of the IGPRG.”
-
Maximising benefits, minimising harms in population health screening
Population screening is an important contributor to advancing health outcomes through the early detection of and successful intervention for chronic disease. The evolution of science, technology and evidence relating to diseases which are or may be amenable to a population screening approach deserve broad discussion and the sharing of expertise and evidence. They also warrant close scrutiny in context of health policy and health resource allocation considerations.
In March, Public Health Association of Australia (PHAA) convened Screening Conference Conference 2025 with the theme of ‘Population Screening for Chronic Disease – Maximising Benefits, Minimising Harms’.
-
Gavin Fox-Smith talks Medical Technology
Former Johnson & Johnson ANZ Managing Director, Gavin Fox-Smith on working in large & small MedTech companies
-
Indigenous physio leadership
On the eve of NAIDOC week 2023, Australian Health Journal met with Scott Willis, the National President of the Australian Physiotherapy Association, a proud Palawa man and the first Indigenous President of the Australian health peak body.
